NEJM This Week NEJM This Week — May 29, 2025
May 28, 2025
Delve into breakthroughs in treating pulmonary arterial hypertension and giant-cell arteritis. Discover the implications of losing Medicare subsidies and how it could threaten patient lives. Navigate the complexities of diagnosing cancer without a known primary site through compelling case studies. Explore innovative solutions for snakebite treatments while addressing primary care shortages in the U.S. Finally, hear a touching narrative about the challenges of caring for a loved one with Alzheimer's disease.
AI Snips
Chapters
Transcript
Episode notes
Sotatercept Advances PAH Care
- Sotatercept improves exercise capacity and reduces death risk in advanced pulmonary arterial hypertension.
- It represents a significant therapeutic advance and may offer long-term clinical stability.
Oral Semaglutide Reduces CV Events
- Oral semaglutide lowers major cardiovascular event risk in high-risk type 2 diabetes.
- It may expand indications for oral GLP-1 receptor agonists similar to injectables.
Upadacitinib Benefits Giant Cell Arteritis
- Upadacitinib at 15 mg oral dose is effective and safe for giant cell arteritis.
- It offers a new glucocorticoid-sparing treatment option for this vasculitis.